EX-10.23 2 htgm-ex1023_1405.htm EX-10.23 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested UnderMaster Assay Development, Commercialization and Manufacturing Agreement • May 5th, 2020 • Delaware
First Amendment to Master Assay Development, Commercialization and Manufacturing AgreementMaster Assay Development, Commercialization and Manufacturing Agreement • August 8th, 2017 • HTG Molecular Diagnostics, Inc • Laboratory analytical instruments
First Amendment to Master Assay Development, Commercialization and Manufacturing Agreement (“Amendment”), dated June 14, 2017, is by and between HTG Molecular Diagnostics, Inc., a corporation organized under the laws of the State of Delaware, U.S., with a place of business at 3430 E. Global Loop, Tucson, AZ 85706 and QIAGEN Manchester Limited, a corporation organized under the laws of the United Kingdom, with a place of business at Skelton House, Lloyd Street North, Manchester, UK.
